@Article{,
AUTHOR = {Malcolm J. Moore},
TITLE = {COUNTERPOINT: Men should be treated for hormone refractory prostate cancer with systemic chemotherapy when they are symptomatic, and not before},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {10},
YEAR = {2003},
NUMBER = {6},
PAGES = {2038--2039},
URL = {http://www.techscience.com/CJU/v10n6/62707},
ISSN = {1488-5581},
ABSTRACT = {The benefits of chemotherapy in men with symptomatic
HRPC include pain relief, better physical functioning
and improved quality of life. These have been well
established in randomized trials. A meaningful or
statistically significant improvement in survival has
yet to be demonstrated. In the absence of a survival
benefit, there is concern that treating men when they
are free of symptoms may have a negative impact upon
quality of life due to drug related toxicity. It will
also limit or eliminate any therapeutic options
when symptoms eventually develop and therapy is
needed most.},
DOI = {}
}